101264-48-6

Basic information

• Product Name: N-BENZYLPIPERIDINE-4-CARBOXAMIDE HYDROCHLORIDE
• Synonyms: N-BENZYL-4-PIPERIDINECARBOXAMIDE HYDROCHLORIDE;N-benzylpiperidine-4-carboxamide(SALTDATA: HCl);N-Benzyl-4-piperidinecarboxamide
• CAS NO: 101264-48-6
• Molecular Formula: C₁₃H₁₈N₂O
• Molecular Weight: 254.76
• Mol File: 101264-48-6.mol

Chemical Properties

• Melting Point: 115-117 °C
• Boiling Point: 437.2 °C at 760 mmHg
• Flash Point: 179.9 °C
• Appearance: /
• Density: 1.073 g/cm³
• Vapor Pressure: 7.64E-08mmHg at 25°C
• PKA: 15.93±0.20(Predicted)
• CAS DataBase Reference: N-BENZYLPIPERIDINE-4-CARBOXAMIDE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-BENZYLPIPERIDINE-4-CARBOXAMIDE HYDROCHLORIDE(101264-48-6)
• EPA Substance Registry System: N-BENZYLPIPERIDINE-4-CARBOXAMIDE HYDROCHLORIDE(101264-48-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 101264-48-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-Benzylpiperidine-4-carboxamide hydrochloride is used as an intermediate in the synthesis of medications for its ability to interact with neurotransmitter receptors, particularly those related to the central nervous system.
Used in Central Nervous System Medications:
It is employed as a key component in the development of drugs that target the central nervous system, leveraging its antagonistic properties for neurotransmitter receptors to manage various neurological conditions.
Used in Analgesic and Anesthetic Agents:
N-Benzylpiperidine-4-carboxamide hydrochloride is used as an active pharmaceutical ingredient in the formulation of analgesic and anesthetic agents due to its inherent pain-relieving and numbing effects.
Used in Research and Development:
N-BENZYLPIPERIDINE-4-CARBOXAMIDE HYDROCHLORIDE is utilized in research settings to explore its pharmacological properties, with the aim of discovering new drug candidates for the treatment of neurological disorders and other conditions that affect the central nervous system.
Used in Drug Development for Neurological Disorders:
N-Benzylpiperidine-4-carboxamide hydrochloride is used as a starting point in the development of new drugs intended to treat a range of neurological disorders, capitalizing on its interaction with neurotransmitter receptors to modulate neuronal activity and alleviate symptoms.

InChI:InChI=1/C13H18N2O/c16-13(12-6-8-14-9-7-12)15-10-11-4-2-1-3-5-11/h1-5,12,14H,6-10H2,(H,15,16)/p+1

Upstream product

• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 
• 100-46-9 benzylamine 
• 188527-08-4 N-(tert-butoxycarbonyl)-4-(4-phenylmethyl-amidoacetyl)piperidine 
• 350716-60-8 piperidine-1,4-dicarboxylic acid mono-(4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-heptadecafluoro-1,1-dimethylundecyl) ester 
• 1026416-11-4 4-benzylcarbamoyl-piperidine-1-carboxylic acid 4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-heptadecafluoro-1,1-dimethyl-undecyl ester 
• 6320-63-4 isonicotinic acid benzylamide 
• 39546-32-2 4-carboxamidopiperidine 
• 100-39-0 benzyl bromide 
• 498-94-2 isonipecotic acid 

Downstream Products

• 1043689-45-7 N-benzyl-1-(4-chlorobenzyl)piperidine-4-carboxamide 
• 1089340-05-5 N-benzyl-1-(4-methylbenzyl)piperidine-4-carboxamide 
• 177948-71-9 4-(benzylaminomethyl)piperidine 
• 1401619-10-0 N-benzyl-1-(1-(4-chlorobenzyl)-3-methyl-1H-indole-2-carbonyl)piperidine-4-carboxamide 
• 1401619-09-7 N-benzyl-1-(1-(4-chlorobenzyl)-7-methyl-1H-indole-2-carbonyl)piperidine-4-carboxamide 
• 1242436-68-5 1-[3-(3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl)-propyl]-piperidine-4-carboxylic acid benzylamide 
• 1104937-24-7 1-[2-(benzyl-phenyl-amino)-1-methyl-ethyl]-piperidine-4-carboxylic acid benzylamide 
• 1104937-26-9 1-(1-methyl-3,3-diphenyl-propyl)-piperidine-4-carboxylic acid benzylamide 

Relevant articles and documents

Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity

HDAC8 has been established as one of the vital targets as far as the cancer is concerned. Different compounds having potential HDAC inhibitory activity have been approved by USFDA. However, none of these compounds are selective towards specific HDAC isoform. In this current study, some new hydroxamate derivatives with alkylpiperidine and alkylpiperazine linker moieties have been designed, synthesized and biologically evaluated. All these compounds are effective HDAC8 inhibitors comprising more or less similar cytotoxic potential against different cancer cell lines. It is observed that the piperazine scaffold containing compound is more active than the compound with piperidine scaffold for exerting HDAC8 inhibitory activity. Moreover, the 4-quinolyl cap group is better than the biphenyl group which is better than the benzyl group for producing higher HDAC8 inhibition as well as cytotoxicity. These compounds displayed selective HDAC8 inhibition over HDAC3. Moreover, these compounds showed an increased caspase3/7 activity suggesting their anticancer potential through modulation of apoptotic pathways. Molecular docking study with three potent compounds was performed with both HDAC3 and HDAC8 enzymes to understand the selectivity profile of these compounds. Compound containing 4-quinolyl cap group with alkyl piperazinyl urea linker moiety has been emerged out as the lead molecule that may be further modified to design more effective and selective HDAC8 inhibitors in future.

SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS

Provided herein are compounds of the Formula I: (I) or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Design, synthesis, and biological evaluation of novel piperidine-4- carboxamide derivatives as potent CCR5 inhibitors

Based on a putative 'Y shape' pharmacophore model of CCR5 inhibitors, a series of novel piperidine-4-carboxamide derivatives were designed and synthesized using a group-reverse strategy. Among synthesized target compounds, 16g (IC50 = 25.73 nM) and 16i (IC50 = 25.53 nM) showed equivalent inhibitory activity against CCR5 to that of the positive control maraviroc (IC50 = 25.43 nM) in calcium mobilization assay. Selected compounds were further tested for their antiviral activity in HIV-1 single cycle assay. Two compounds, 16g and 16i, displayed antiviral activity with IC 50 values of 73.01 nM and 94.10 nM, respectively. Additionally, the pharmacokinetic properties and inhibitory potency against hERG of 16g were evaluated, providing a foundation for ongoing optimization.

Antiplasmodial activity of piperazine sulfonamides

A high-throughput screening program identified two piperazine sulfonamides with activity against Plasmodium falciparum. Both screening positives had three structural features with potential liabilities: furanyl, thiourea and nitrophenyl groups. The furan could be replaced with no loss of activity, replacement of the nitrophenyl led to some loss of activity, and any attempt to replace the thiourea led to a significant decrease in activity, which implicates this reactive functional group's role in the antiplasmodial activity of this compound class.

Discovery of N-{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl] piperidin-4-yl}-2-phenylacetamide (Lu AE51090): An allosteric muscarinic M 1 receptor agonist with unprecedented selectivity and procognitive potential

The discovery and Structure-activity relationship (SAR) of a series of allosteric muscarinic M1 receptor agonists are described. Compound 17 (Lu AE51090) was identified as a representative compound from the series, based on its high selectivity as an agonist at the muscarinic M1 receptor across a panel of muscarinic receptor subtypes. Furthermore, 17 displayed a high degree of selectivity when tested in a broad panel of G-protein-coupled receptors, ion channels, transporters, and enzymes, and 17 showed an acceptable pharmacokinetic profile and sufficient brain exposure in rodents in order to characterize the compound in vivo. Hence, in a rodent model of learning and memory, 17 reversed delay-induced natural forgetting, suggesting a procognitive potential of 17.

Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for σ1 receptor ligands based on a series of substituted benzo[d ]oxazol-2(3H)-one derivatives

Novel benzo[d ]oxazol-2(3H)-one derivatives were designed and synthesized, and their affinities against σ receptors were evaluated. On the basis of 31 compounds, a three-dimensional pharmacophore model for the σ1 receptor binding site was devel

Fluorous Boc (FBoc) carbamates: New amine protecting groups for use in fluorous synthesis

The first fluorous variants of the Boc (tert-butyloxycarbonyl) group have been prepared and tested for their suitability as nitrogen protecting groups. A group with two fluorous chains and an ethylene spacer, (RfCH2CH2)2(CH3)COC(O)-, was readily attached to a representative amine but was difficult to cleave. In contrast, groups with two fluorous chains and a propylene spacer, (RfCH2CH2CH2)2-(CH3) COC(O)-, or one fluorous chain and an ethylene spacer, (RfCH2CH2)(CH3)2COC(O)-, were readily formed and cleaved. The fluorous alcohol component of the FBoc group can be removed by evaporation and can be recovered and reused. The utility of the new FBoc group (C8F17CH2CH2)(CH3) 2COC(O)- was demonstrated in 16 and 96 compound library synthesis exercises. Separations can be achieved either by manual, parallel fluorous solid-phase extraction, or automated, serial fluorous chromatography. The results provide additional confirmation of the value of "light" fluorous synthesis techniques, and the new fluorous Boc groups expand the applicability of fluorous synthesis techniques to many classes of nitrogen-containing organic compounds.

THF-CONTAINING SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE

The present invention relates to a class of THF-containing sulfonamides which are aspartyl protease inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention.